These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 9203846)

  • 1. Growth factor receptors as molecular targets for cancer diagnosis and therapy.
    Zalutsky MR
    Q J Nucl Med; 1997 Jun; 41(2):71-7. PubMed ID: 9203846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
    Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
    Reist CJ; Garg PK; Alston KL; Bigner DD; Zalutsky MR
    Cancer Res; 1996 Nov; 56(21):4970-7. PubMed ID: 8895752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA; Wikstrand CJ; Batra SK; Bigner DD; Pastan I
    Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
    Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF; Reist CJ; Bigner DD; Zalutsky MR
    Cancer Res; 2000 Aug; 60(16):4453-60. PubMed ID: 10969792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
    Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells.
    Dean GS; Pusztai L; Xu FJ; O'Briant K; DeSombre K; Conaway M; Boyer CM; Mendelsohn J; Bast RC
    Clin Cancer Res; 1998 Oct; 4(10):2545-50. PubMed ID: 9796989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4.
    Yang W; Barth RF; Wu G; Kawabata S; Sferra TJ; Bandyopadhyaya AK; Tjarks W; Ferketich AK; Moeschberger ML; Binns PJ; Riley KJ; Coderre JA; Ciesielski MJ; Fenstermaker RA; Wikstrand CJ
    Clin Cancer Res; 2006 Jun; 12(12):3792-802. PubMed ID: 16778107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
    Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
    Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G; Hewit TH; Holmes M; Valerie K; Hawkins W; Lin PS; Mikkelsen RB; Schmidt-Ullrich RK
    Clin Cancer Res; 2004 Oct; 10(19):6732-43. PubMed ID: 15475464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III.
    Zeineldin R; Rosenberg M; Ortega D; Buhr C; Chavez MG; Stack MS; Kusewitt DF; Hudson LG
    Mol Carcinog; 2006 Nov; 45(11):851-60. PubMed ID: 16788982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
    Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.